Advertisement

Topics

Arcus Biosciences Announces $107 Million Series C Financing Led by GV and Initiation of Two Clinical Trials

07:30 EST 13 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Arcus Biosciences, a clinical-stage biotechnology company focused on the discovery and development of innovative cancer immunotherapies, announced today the completion of a $107 million Series C financing. This financing brings ...

Other Sources for this Article

Arcus Biosciences
Jennifer Jarrett, 510-694-6261
Chief Business and Financial Officer
jjarett@arcusbio.com

NEXT ARTICLE

More From BioPortfolio on "Arcus Biosciences Announces $107 Million Series C Financing Led by GV and Initiation of Two Clinical Trials"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...